GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Triple Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer
Interventions: DRUG: cisplatin|OTHER: laboratory biomarker analysis|OTHER: pharmacological study|PROCEDURE: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|DRUG: GDC -0941
Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)|Genentech, Inc.